Attgeno Patents

Patent portfolio assigned to Attgeno (verified via public assignee records). Estimated patent count: 3. Swedish pharma (Karolinska spinout, founded 2005), lead candidate Supernitro/PDNO, an IV nitric-oxide donor for acute pulmonary hypertension; completed Phase IIa. Patents assigned to Attgeno AB incl. US8030511B2 plus related applications US20090258944 and US20080293813. Pre-revenue clinical-stage, so no named customers/competitors.